Atogepant for the Preventive Treatment of Migraine in Japanese Participants: A Phase 3, Open-Label, 52-Week Extension Study
Authors
- Gina Ahmadyar (ORCID: https://orcid.org/0000-0002-9235-2876)
- Shigeya Tanaka (ORCID: https://orcid.org/0000-0003-1012-3736)
- Giovanna Forero
- Yasuhiko Matsumori (ORCID: https://orcid.org/0000-0001-5852-0146)
- Toshimasa Yamamoto
- Krisztian Nagy
- Jia Bao
- Takao Takeshima
- Akihiro Takahashi
- Rosa de Abreu Ferreira
- Hua Guo
Institutions
- AbbVie (United States) (US)
- Kagoshima Prefectural College (JP)
- Tominaga hospital (JP)
- Sapporo Science Center (JP)
- Saitama Medical University (JP)